Since the MyD88-dependent signaling pathway leads to the early phase of NF-κB activation whereas the MyD88-independent signaling pathway initiates the late phase of NF-κB activation, this suggests that both mechanisms might be utilized in CLL. The gene discussed is MYD88; the disease is B-cell chronic lymphocytic leukemia.